Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

GlycoMimetics, Inc. (GLYC)

Pharmaceutical Preparations

https://www.glycomimetics.com

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.

9708 MEDICAL CENTER DRIVE
ROCKVILLE, MD

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/10/2014

Market Cap

11,626,465

Shares Outstanding

64,390,000

Weighted SO

64,393,294

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

MLYS --.--%

FHTX --.--%

IVA --.--%

DYN --.--%

LIFE --.--%

TRVI --.--%

CUE --.--%

ANTX --.--%

Beta

2.1850

Last Div

0.0000

Range

0.17-3.53

Chg

0.0011

Avg Vol

3815120

Mkt Cap

11626465

Exch

NASDAQ

Country

US

Phone

240 243 1201

DCF Diff

-0.4310

DCF

0.6470

Div Yield

0.0000

P/S

1162.6465

EV Multiple

0.0010

P/FV

0.5795

Div Yield %

0.0000

P/E

-0.2972

PEG

-0.0044

Payout

0.0000

Current Ratio

5.4765

Quick Ratio

5.4765

Cash Ratio

5.1388

DSO

2799.9150

DIO

0.0000

Op Cycle

2799.9150

DPO

1083.5261

CCC

1716.3889

Gross Margin

-31.0277

Op Margin

-984455.9720

Pretax Margin

-3911.4073

Net Margin

-3911.4073

Eff Tax Rate

0.0018

ROA

-1.6018

ROE

-1.1681

ROCE

-490.6945

NI/EBT

1.0000

EBT/EBIT

0.0040

EBIT/Rev

-984455.9720

Debt Ratio

0.0184

D/E

0.0224

LT Debt/Cap

0.0000

Total Debt/Cap

0.0219

Int Coverage

-16915.6324

CF/Debt

-79.5508

Equity Multi

1.2171

Rec Turnover

0.1304

Pay Turnover

0.3369

Inv Turnover

0.0000

FA Turnover

0.0236

Asset Turnover

0.0004

OCF/Share

-0.5536

FCF/Share

-0.5539

Cash/Share

0.3472

OCF/Sales

-3570.0394

FCF/OCF

1.0005

CF Coverage

-79.5508

ST Coverage

-79.5508

CapEx Coverage

-1915.3599

Div&CapEx Cov

-1915.3599

P/BV

0.5795

P/B

0.5795

P/S

1162.6465

P/E

-0.2972

P/FCF

-0.3255

P/OCF

-0.3257

P/CF

-0.3257

PEG

-0.0044

P/S

1162.6465

EV Multiple

0.0010

P/FV

0.5795

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 18, 22:49 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NDOI, SSBK, BRDG on Behalf of Shareholders GlobeNewswire Inc. May 18, 22:49 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, LRFC, RDW, GLYC on Behalf of Shareholders GlobeNewswire Inc. May 06, 22:40 $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – GLYC, BRZH, PRA, FVNNU GlobeNewswire Inc. Nov 05, 23:46 INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYC

Revenue Product Segmentation